Skip to content
Screener

CytomX Therapeutics CTMX Q4 2025 Annual earnings

Reported March 16, 2026 · Before market open

Revenue$661.0KMiss by $6.7M
EPS-$0.22Miss by $0.14
Revenue estimate$7.3M
EPS estimate-$0.08

Next report

Nov 5, 2026 (in 2 months)
Revenue estimate$10.4M
EPS estimate-$0.09

Financials

Q4 2025

Income statement

See full
Revenue$663.0K-98.3%
Operating income-$27.9M-258%
Net income-$26.5M-240%
EPS (diluted)-$0.22-196%

Balance sheet

See full
Cash & equivalents$12.7M-66.7%
Total debt$4.2M-54.8%
Total equity$99.0M+21,812%
Total assets$151.6M+25.7%

Cash flow

See full
Operating cash flow-$23.2M-16.8%
CapEx$201.0K+151%
Free cash flow-$23.4M-17.3%

Valuation & ratios

Valuation

as of 12/31/25
See full
Market cap$721.79M+795%
Enterprise value$713.37M+1,273%
P/S9.5×+8.9×

Profitability

See full
Operating margin-29.4%-47.4pp
Net margin-22.8%-45.9pp
FCF margin-99.5%+142pp

Returns & leverage

See full
Debt / equity0×—
Current ratio3.1×+1.8×

FAQ

When did CytomX Therapeutics report Q4 2025 earnings?
CytomX Therapeutics (CTMX) reported Q4 2025 earnings on March 16, 2026 before market open.
What were CytomX Therapeutics's Q4 2025 revenue and EPS?
CytomX Therapeutics reported revenue of $661.0K and eps of $-0.22 for Q4 2025.
Did CytomX Therapeutics beat estimates in Q4 2025?
Revenue missed the consensus estimate of $7.3M by $6.7M. EPS missed the consensus estimate of $-0.08 by $0.14.
How did CytomX Therapeutics's Q4 2025 results compare year-over-year?
Compared to the same quarter a year prior, revenue declined 98.3% from $38.1M a year earlier.
Where can I find CytomX Therapeutics's Q4 2025 SEC filings?
You can read the 8-K earnings release (0001193125-26-107152) and the 10-K periodic report (0001193125-26-107146) directly on SEC EDGAR. The filing index links above go to sec.gov.